EFPIA calls for new debate on drug pricing
This article was originally published in SRA
Executive Summary
The research-based pharmaceutical industry is looking at new ways to best characterise the “value for money” offered by their products following the spate of announcements by certain European Union member states of drug price cuts in response to the economic crisis1,2. Vibha Sharma reports from the press conference preceding the 2010 general meeting of European pharmaceutical industry association, EFPIA, held in London from 21-22 June.